Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors.

Eolia BrissotMyriam LabopinIan MoiseevJ J CornelissenEllen MeijerGwendolyn Van GorkomMontserrat RoviraFabio CiceriLaimonas GriskeviciusDidier BlaiseEdouard ForcadeMartin MistrikStephan MielkeClaude Eric BulaboisRiitta NiittyvuopioEric DeconinckAnnalisa RuggeriJaime SanzAlexandros SpyridonidisBipin SavaniSebastian GiebelArnon NaglerMohamad Mohty

Published in: Journal of hematology & oncology (2020)

These results highlight that, in the10/10 HLA-MUD setting, the use of PTCY for GVHD prophylaxis may provide similar outcomes to those obtained with ATG in patients with AML in CR1.

Keyphrases

stem cell transplantation
acute myeloid leukemia
high dose
allogeneic hematopoietic stem cell transplantation
low dose
cord blood
acute lymphoblastic leukemia
ulcerative colitis
type diabetes
kidney transplantation
metabolic syndrome
adipose tissue
systemic lupus erythematosus
skeletal muscle